

Electronic Health Record: Access, Share, Expand Project

Overview of stakeholder feedback received

Joint PCWP and HCPWP virtual meeting, 2 June 2020





Initial Stakeholder Input

- BEUC The European Consumer Organisation
- CPME Standing Committee of European Doctors
- EHN European Heart Network
- EPF European Patient Forum
- EULAR- European League Against Rheumatism
- EURODIS Rare Disease Europe
- PGEU Pharmaceutical Group of the European Union







Initial Stakeholder Input



Input provided based on shared


- Position papers
- Publications in scientific literature
- Guiding principles
- Comments on GDPR consultation
- Comments on strategic reflection to the EMA Regulatory Science to 2025
- Points to consider documents
- Working documents






Key Topics raised in the context of health data

















Key Topics raised in the context of health data =>

Translates into:

















Ongoing initiatives

- Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions: <u>A European strategy for</u> data
- Commission Experts' Workshops Assessment of the Member States' rules on health data in the light of the GDPR 2019/2020
- <u>Joint Action</u> addressing differences in national General Data Protection Regulation (GDPR) implementation in the health sector, including the European Health Data Space and the health data use/eHealthAction <u>Innovative use of Health Data</u>
- Commission White Paper on 'Artificial Intelligence A European approach to excellence and trust
- European Parliament Report on a <u>Framework of ethical aspects of artificial intelligence</u>, robotics and related technologies
- European Parliament Study <u>The ethics of artificial intelligence: Issues and initiatives</u>



Next Steps

- Your input is important to determine the content of the "Q&As on the GDPR and the Secondary Use of Data for Medicines and Public Health Purposes".
- Please submit specific data protection questions (possibly with examples)
 by 10 July 2020 to dpconsultation@ema.europa.eu
- EMA will consolidate your input and will aim to put your questions in context of operational scenarios such as medicine development, marketing authorisation approvals and post-authorisation safety monitoring.



Any questions?



Further information

Sabine.Brosch@ema.europa.eu; Orsolya.Eotvos@ema.europa.eu

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000

